by Paul McIntosh | Apr 21, 2022 | 2022, Press Releases
New preclinical data further support the application of NM002 as novel anti-inflammatory-antimicrobial intervention in community acquired pneumonia and also data demonstrate the in vitro safety profile, fungal cell specificity and potential of NP339 in respiratory...
by Paul McIntosh | Jan 4, 2022 | 2022, Events
Aberdeen, January 4, 2022 – NovaBiotics Ltd, a privately held clinical stage company developing novel immune based therapies for life-threatening and life-limiting-diseases, today announced that Dr Deborah O’Neil OBE, FRSE, Chief Executive Officer of...
Recent Comments